News and Announcements
Actinogen Published in British Journal of Pharmacology
- Published February 09, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Actinogen Medical is pleased to announce the research paper: Selection and early clinical evaluation of the brain-penetrant hydroxysteroid dehydrogenade type 1 inhibitor UE2343 (Xanamem™) has been published in the British Journal of Pharmacology.
KEY TAKEAWAYS:
- These Phase I results show Xanamem™ is safe and well tolerated with no major safety issues.
- Confirm the brain penetrating properties of Xanamem™ and that it reaches the brain at concentrations predicted to inhibit excess cortisol production in the brain.
- Xanamem™ is a good candidate to further investigate as a treatment for Alzheimer’s disease.
For more information please click below.
Company Updates
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
Backed By Leading Investment Groups and Family Offices
